- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00593723
IMRT Tomotherapy for Esophagus Cancer (IMRT)
IMRT Tomotherapy for Esophagus Cancer: A Phase I Feasibility Study in Non-Operative Patients
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Missouri
-
St. Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age >= 18
- Karnofsky Performance Status of >= 60
- TNM Stages T1-4, N0-3, M0
- Pathologic confirmation of esophagus cancer
- Evaluation by medical oncologist determines that the patient is medically fit for concurrent chemotherapy
- Evaluation by surgeon determines that patient is unresectable
Exclusion Criteria:
- Age < 18
- Karnofsky Performance Status < 60
- Radiographic or pathologic evidence of distant metastatic disease (classified as M1b in AJCC staging manual)
- Prior radiation therapy to the thorax or upper abdomen, preventing definitive radiation therapy.
- Pregnant or lactating, if female.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: IMRT + Concurrent chemotherapy
180 cGy daily fractions to a total dose of 5400 cGy to PTV1 and 200 cGy daily fractions to a total dose of 6000 cGy to PTV2. Once a day, five days a week, for approximately 6 weeks. Planned chemotherapy: cisplatin (75 mg/m2) day 1 and 5-FU (1000 mg/m2) days 1-4 on weeks 1, 5, 10, and 14 of therapy. Please note that drug regimens and doses may vary and will be at the discretion of the medical oncologist. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
The study will evaluate the feasibility of using helical tomotherapy to deliver IMRT in patients with unresectable esophagus cancer.
Tidsramme: One year after protocol registration
|
The study will be deemed infeasible if one or more of the following results occur:
|
One year after protocol registration
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Evaluate local recurrence rates
Tidsramme: Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate disease-free survival rates
Tidsramme: Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate regional recurrence rates
Tidsramme: Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate distant recurrence rates
Tidsramme: Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Evaluate overall survival rates
Tidsramme: Until patient progressive disease or death
|
6 weeks after therapy, every 3 months for first two years post therapy, every 6 months for years 3, 4, and 5 post therapy, and then annually.
|
Until patient progressive disease or death
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Jeffrey Bradley, MD, Washington University School of Medicine
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 06-1070 / 201105499
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Spiserørskræft
-
Erbe Elektromedizin GmbHNAMSA; Kansas City Veteran Affairs Medical Center; Erbe USA IncorporatedAfsluttetBarretts spiserør | Højgradig dysplasi i Barrett-esophagus | Lavgradig dysplasi i Barrett-esophagusForenede Stater
-
Maria Sklodowska-Curie National Research Institute...Centre of Postgraduate Medical EducationAfsluttetBarretts esophagus med lavgradig dysplasi
-
Tomasz RomańczykAfsluttetHeterotopisk maveslimhinde i den proksimale esophagusPolen
-
University Medical Center GroningenAfsluttetSpiserørskræft | Barrett Esophagus | Dysplasi i Barrett EsophagusHolland
-
Johns Hopkins UniversityAmerican Society for Gastrointestinal Endoscopy; Pentax Medical CorporationAfsluttetBarretts esophagus, esophageal intraepithelial neoplasiForenede Stater, Tyskland
-
Coordinación de Investigación en Salud, MexicoRekrutteringIntestinal Metaplasi | Dysplasi | Barretts esophagus med lavgradig dysplasiMexico
-
International Agency for Research on CancerUniversity of Cambridge; Kilimanjaro Clinical Research InstituteAfsluttet
-
Nantes University HospitalRekruttering
-
Columbia UniversityNational Cancer Institute (NCI); University of MichiganRekruttering
-
Professor Michael BourkeRekrutteringBarretts spiserørAustralien
Kliniske forsøg med IMRT
-
Cancer Institute and Hospital, Chinese Academy...UkendtSmåcellet lungekræftKina
-
National Cancer Institute, EgyptAktiv, ikke rekrutterende
-
St. Jude Children's Research HospitalMayo ClinicAfsluttetAbdominalt neuroblastomForenede Stater
-
Sun Yat-sen UniversityAktiv, ikke rekrutterendeLivskvalitet | Dødelighed | Nasopharyngeale neoplasmer | KomplikationerKina
-
Jiangsu Cancer Institute & HospitalIkke rekrutterer endnuStadie IVA Nasopharyngeal CarcinomKina
-
Radiation Therapy Oncology GroupNational Cancer Institute (NCI); NRG OncologyAfsluttetSeksuel dysfunktion | Prostatakræft | Strålingstoksicitet | Psykosociale virkninger af kræft og dens behandlingForenede Stater, Canada
-
Royal Marsden NHS Foundation TrustAfsluttet
-
University of Michigan Rogel Cancer CenterAfsluttetBrystkræftForenede Stater
-
Washington University School of MedicineAfsluttetHoved- og halskræftForenede Stater
-
Alberta Health servicesAfsluttet